Edit |   |
---|---|
Antigenic Specificity | IGF1R/CD221 (Teprotumumab biosimilar) |
Clone | monoclonal |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG1-ND |
Format | Protein A/G purified |
Size | 100 µg, 1 mg, |
Concentration | typically between 0.5-2.0 mg/ml. |
Applications | ELISA, WB |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Teprotumumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IGF1R/CD221, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. 8 Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received ""breakthrough therapy"" designation from the FDA in 20163 and was approved by the FDA in January 2020 for the treatment of TED. 7 Thyroid eye disease is a potentially debilitating complication of Graves' Disease involving inflammation and tissue remodeling behind the eye, and previous treatment options typically involved multiple invasive surgeries - teprotumumab is the first drug ever approved for the treatment of TED and therefore represents a significant step forward in the treatment this disease. |
Immunogen | n/a |
Other Names | Teprotumumab, IGF1R/CD221, 1036734-93-6 |
Gene, Accession # | CAS: 1036734-93-6 |
Catalog # | abx831196 |
Price | please inquire |
Order / More Info | IGF1R/CD221 (Teprotumumab biosimilar) Antibody from ABBEXA LTD |
Product Specific References | n/a |
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950